Genmab Shares Outstanding 2009-2021 | GNMSF

Genmab shares outstanding history from 2009 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Genmab shares outstanding for the quarter ending September 30, 2021 were 0.661B, a 902.32% increase year-over-year.
  • Genmab 2020 shares outstanding were 0.066B, a 3.53% increase from 2019.
  • Genmab 2019 shares outstanding were 0.064B, a 2.57% increase from 2018.
  • Genmab 2018 shares outstanding were 0.062B, a 0.08% decline from 2017.
Genmab Annual Shares Outstanding
(Millions of Shares)
2020 66
2019 64
2018 62
2017 62
2016 62
2015 61
2014 57
2013 52
2012 46
2011 45
2010 45
2009 45
2008 45
2007 44
Genmab Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 661
2021-06-30 66
2021-03-31 66
2020-12-31 66
2020-09-30 66
2020-06-30 66
2020-03-31 66
2019-12-31 64
2019-09-30 65
2019-06-30 63
2019-03-31 62
2018-06-30 62
2018-03-31 62
2017-12-31 62
2017-09-30 63
2017-06-30 62
2017-03-31 6
2016-12-31 62
2016-09-30 62
2016-06-30 62
2016-03-31 61
2015-12-31 61
2015-09-30 62
2015-06-30 61
2015-03-31 60
2014-12-31
2014-09-30 58
2014-06-30 57
2014-03-31 56
2013-12-31
2013-09-30 53
2013-06-30 51
2013-03-31 52
2012-12-31
2012-09-30 45
2012-06-30 43
2012-03-31 45
2011-12-31
2011-09-30 45
2011-06-30 45
2011-03-31 45
2010-12-31 45
2010-09-30 45
2010-06-30 45
2010-03-31 45
2009-12-31 45
2009-09-30 43
2009-06-30 44
2009-03-31 46
2008-12-31 45
2008-06-30 49
2008-03-31 44
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $23.076B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75